Nonprofit group gains right to develop rilpivirine for HIV prevention

09/25/2013 | Genetic Engineering & Biotechnology News

PATH, an international nonprofit organization, has been granted rights through a deal with Janssen R&D of Ireland to develop an injectable form of the HIV-1 drug rilpivirine as a potential preventive treatment for HIV. Backed by the Bill & Melinda Gates Foundation, PATH plans to carry out prophylaxis trials in partnership with the HIV Prevention Trials Network and the NIH's AIDS division. PATH and Janssen could enter a late-stage development deal based on the results of the trial.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI